# An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

> **NCT02831673** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 719 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** Dolutegravir (DTG)
- **DRUG:** Lamivudine (3TC)
- **DRUG:** Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)

## Key facts

- **NCT ID:** NCT02831673
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-21
- **Primary completion:** 2018-03-29
- **Final completion:** 2022-08-15
- **Target enrollment:** 719 (ACTUAL)
- **Last updated:** 2023-08-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831673, "An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT02831673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*